Drug-Sensitivity and DNA-Binding of a Subform of Topoisomerase Iiα in Resistant Human HL-60 Cells

References

• Osheroff N, Zechiedrich E L, Gale K C. Catalytic function of DNA topoisomerase II. Bioessays 1991; 13: 269–73
   PubMed Web of Science ®Google Scholar
• Woessner R D, Chung T D, Hofmann G A, et al. Differences between normal and ras-transformed NIH-3T3 cells in expression of the 170 kD and 180 kD forms of topoisomerase II. Cancer Res 1990; 50: 2901–8
   PubMed Web of Science ®Google Scholar
• Woessner R D, Mattern M R, Mirabelli C K, Johnson R K, Drake F H. Proliferation- and cell cycle-dependent differences in expression of the 170 kilodalton and 180 kilodalton forms of topoisomerase II in NIH-3T3 cells. Cell Growth Differ 1991; 2: 209–14
   PubMedGoogle Scholar
• Kaufmann S H, McLaughlin S J, Kastan M B, Liu L F, Karp J E, Burke P J. Topoisomerase II levels during granulocytic maturation in vitro and in vivo. Cancer Res 1991; 51: 3534–43
   PubMed Web of Science ®Google Scholar
• Collett A G, Ralph R K. Regulation of topoisomerase II by murine mastocytoma cells. Biochim Biophys Acta 1992; 1132: 259–64
   PubMedGoogle Scholar
• Capranico G, Tinelli S, Austin C A, Fisher M L, Zunino F. Different patterns of gene expression of topoisomerase II isoforms in differentiated tissues during murine development. Biochim Biophys Acta 1992; 1132: 43–8
   PubMedGoogle Scholar
• Lim M, Liu L F, Jacobson K D, Williams J R. Induction of sister chromatid exchanges by inhibitors of topoisomerases. Cell Biol Toxicol 1986; 2: 485–94
   PubMed Web of Science ®Google Scholar
• Tan K B, Dorman T E, Falls K M, et al. Topoisomerase II alpha and topoisomerase II beta genes: characterization and mapping to human chromosomes 17 and 3, respectively. Cancer Res 1992; 52: 231–4
   PubMed Web of Science ®Google Scholar
• Jenkins J R, Ayton P, Jones T, et al. Isolation of cDNA clones encoding the beta isozyme of human DNA topoisomerase II and localisation of the gene to chromosome 3p24. Nucleic Acids Res 1992; 20: 5587–92
   PubMed Web of Science ®Google Scholar
• Drake F H, Hofmann G A, Bartus H F, Mattern M R, Crooke S T, Mirabelli C K. Biochemical and pharmacological properties of p170 and p180 forms of topoisomerase II. Biochemistry 1989; 28: 8154–60
   PubMed Web of Science ®Google Scholar
• Holden J A, Rolfson D H, Wittwer C T. The distribution of immunoreactive topoisomerase II protein in human tissues and neoplasms. Oncol Res 1992; 4: 157–66
   PubMed Web of Science ®Google Scholar
• Liu L F. DNA topoisomerase poisons as antitumor drugs. Annu Rev Biechem 1989; 58: 351–75
   PubMed Web of Science ®Google Scholar
• Lock R B, Ross W E. DNA topoisomerases in cancer therapy. Anticancer Drug Des 1987; 2: 151–64
   PubMedGoogle Scholar
• Zijlstra J G, de Jong S, de Vries E G, Mulder N H. Topoisomerases, new targets in cancer chemotherapy. Med Oncol Tumor Pharmacother 1990; 7: 11–8
   PubMedGoogle Scholar
• Zwelling L A, Estey E, Bakic M, Silberman L, Chan D. Topoisomerase II as a target of antileukemic drugs. NCI Monogr 1987; 1987: 79–82
   Google Scholar
• D'Arpa P, Liu L F. Topoisomerase-targeting antitumor drugs. Biochim Biophys Acta 1989; 989: 163–77
   PubMed Web of Science ®Google Scholar
• Beck W T, Danks M K. Mechanisms of resistance to drugs that inhibit DNA topoisomerases. Semin Cancer Biol 1991; 2: 235–44
   PubMedGoogle Scholar
• Bugg B Y, Danks M K, Beck W T, Suttle D P. Expression of a mutant DNA topoisomerase II in CCRF-CEM human leukemic cells selected for resistance to teniposide. Proc Natl Acad Sci USA 1991; 88: 7654–8
   PubMed Web of Science ®Google Scholar
• Zwelling L A, Mayes J, Deisseroth K, et al. A restriction fragment length polymorphism for human topoisomerase II: possible relationship to drug-resistance. Cancer Commun 1990; 2: 357–61
   PubMed Web of Science ®Google Scholar
• Hinds M, Deisseroth K, Mayes J, et al. Identification of a point mutation in the topoisomerase II gene from a human leukemia cell line containing an amsacrine-resistant form of topoisomerase II. Cancer Res 1991; 51: 4729–31
   PubMed Web of Science ®Google Scholar
• Fry A M, Chresta C M, Davies S M, et al. Relationship between topoisomerase II level and chemosensitivity in human tumor cell lines. Cancer Res 1991; 51: 6592–5
   PubMed Web of Science ®Google Scholar
• Webb Cd, Latham M D, Lock R B, Sullivan D M. Attenuated topoisomerase II content directly correlates with a low level of drug resistance in a Chinese hamster ovary cell line. Cancer Res 1991; 51: 6543–9
   PubMed Web of Science ®Google Scholar
• Gieseler F, Boege F, Erttmann R, . Characterization of human leukemic HL-60 cell sublines as a model for primary and secondary resistance against cytostatics. Hematology and blood transfusion 34, Hiddemann, et al. Springer-Verlag, Berlin-Heidelberg 1992; 44–8
   Google Scholar
• Gieseler F, Boege F, Clark M. Alteration of topoisomerase II action is a possible molecular mechanism of HL-60 cell differentiation. Environ Health Perspect 1990; 88: 183–5
   PubMed Web of Science ®Google Scholar
• Smith P J, Makinson T A. Cellular consequences of overproduction of DNA topoisomerase II in an ataxia-telangiectasia cell line. Cancer Res 1989; 49: 1118–24
   PubMed Web of Science ®Google Scholar
• Boege F, Gieseler F, Biersack H, Clark M. Use of anion-ex-change chromatography and chromatofocussing to reveal the structural and functional heterogeneity of topoisomerase II in a HL-60 cell line resistant to multi-drug treatment. J Chromatogr 1991; 587: 3–9
   PubMed Web of Science ®Google Scholar
• Boege F, Gieseler F, Müller M, Biersack H, Meyer P. Topoisomerase II is activated during partial purification by heparin-sepharose chromatography. J Chromatogr 1992; 625: 67–71
   PubMed Web of Science ®Google Scholar
• Wright W D, Roti R J. Resolution of DNA topoisomerase II by two-dimensional polyacrylamide gel electrophoresis and western blotting. Anal Biochem 1992; 204: 124–30
   PubMed Web of Science ®Google Scholar
• Sahai B M, Kaplan J G. A quantitative decatenation assay for type II topoisomerases. Anal Biochem 1986; 156: 364–79
   PubMed Web of Science ®Google Scholar
• Zwelling L A, Hinds M, Chan D, et al. Characterization of an amsacrine-resistant line of human leukemia cells. Evidence for a drug-resistant form of topoisomerase II. J Biol Chem 1989; 264: 16411–20
   PubMed Web of Science ®Google Scholar
• Meyer P, Boege F, Gieseler F. Topoisomerase II function detected as protein-DNA complexes in two sublines of HL-60 cells. Toxico Lett 1993; 67: 325–30
   PubMed Web of Science ®Google Scholar
• Drake F H, Zimmerman J P, McCabe F L, et al. Purification of topoisomerase II from amsacrine-resistant P388 leukemia cells. Evidence for two forms of the enzyme. J Biol Chem 1987; 262: 16739–47
   PubMed Web of Science ®Google Scholar
• Tamura H, Kohchi C, Yamada R, et al. Molecular cloning of a cDNA of a camptothecin-resistant human DNA topoisomerase I and identification of mutation sites. Nucleic Acids Res 1991; 19: 69–75
   PubMed Web of Science ®Google Scholar
• Kjeldsen E, Bonven B J, Andoh T, et al. Characterization of a camptothecin-resistant human DNA topoisomerase I. J Biol Chem 1988; 263: 3912–6
   PubMed Web of Science ®Google Scholar
• Pommier Y, Kerrigan D, Schwartz R E, Swack J A, McCurdy A. Altered DNA topoisomerase II activity in Chinese hamster cells resistant to topoisomerase II inhibitors. Cancer Res 1986; 46: 3075–81
   PubMed Web of Science ®Google Scholar
• Huff A C, Ward R, Kreuzer K N. Mutational alteration of the breakage/resealing subunit of bacteriophage T4 DNA topoisomerase confers resistance to antitumor agent m-AMSA. Mol Gen Genet 1990; 221: 27–32
   PubMedGoogle Scholar
• Huff A C, Kreuzer K N. Evidence for a common mechanism of action for antitumor and antibacterial agents that inhibit type II DNA topoisomerases. J Biol Chem 1990; 265: 20496–505
   PubMed Web of Science ®Google Scholar
• Huff A C, Leatherwood J K, Kreuzer K N. Bacteriophage T4 DNA topoisomerase is the target of antitumor agent 4′-(9-acridinylamino) methanesulfon-m-aninidide (m-AMSA) in T4-infected Escherichia coli. Proc Natl Acad Sci USA 1989; 86: 1307–11
   PubMed Web of Science ®Google Scholar
• Yamagishi J, Yoshida H, Yamayoshi M, Nakamura S. Nalidixic acid-resistant mutations of the gyrB gene of Escherichia coli. Mol Gen Genet 1986; 204: 367–73
   PubMedGoogle Scholar